Amber Berry
Adult Health · Wethersfield, CTNPI 1821426487
Payments from drug & device makers
Across 49 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$222
- Neurocrine Biosciences, Inc.$111
- AstraZeneca$98
- Astellas Pharma US Inc$54
- GSK$53
- Novo Nordisk$51
- plus $397 from 14 others
What the payments were for
- Food & beverage$986100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $222 |
| Neurocrine Biosciences, Inc. | 1 | $111 |
| AstraZeneca | 5 | $98 |
| Astellas Pharma US Inc | 2 | $54 |
| GSK | 2 | $53 |
| Novo Nordisk | 3 | $51 |
| Amneal Pharmaceuticals LLC | 2 | $46 |
| Johnson & Johnson | 3 | $46 |
| Bayer | 2 | $39 |
| Eisai Inc. | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Pfizer | 2 | $32 |
| Baxter Healthcare | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| Viatris Specialty LLC | 1 | $19 |
| Corcept Therapeutics | 1 | $17 |
| Merck | 1 | $17 |
| Exact Sciences | 1 | $17 |
How this compares
$986 in reported general payments places this provider in the 65th percentile of 418 adult health providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 52 | $75,060 |
| FarxigaDapagliflozin Propanediol | 46 | $51,497 |
| JanuviaSitagliptin Phosphate | 28 | $46,799 |
| OzempicSemaglutide | 37 | $40,619 |
| EliquisApixaban | 26 | $31,455 |
| XareltoRivaroxaban | 25 | $23,876 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 11 | $4,198 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $3,801 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 35 | $2,643 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $2,519 |
| Metoprolol Succinate | 193 | $1,938 |
| Atorvastatin Calcium | 264 | $1,814 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 13 | $1,639 |
| Gabapentin | 97 | $1,554 |
| Omeprazole | 87 | $1,462 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $22 | $75,06052 claims |
| AstraZenecaFarxiga | $98 | $51,49746 claims |
| MerckJanuvia | $17 | $46,79928 claims |
| Novo NordiskOzempic | $51 | $40,61937 claims |
| PfizerEliquis | $32 | $31,45526 claims |
| Johnson & JohnsonXarelto | $46 | $23,87625 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $46 | $1,251143 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 418 adult health providers in Connecticut.
Other adult health in Wethersfield
- Laura MulkaWethersfield$306K
- Kimberly RyanWethersfield$74K
- Leah EhleManchester$418K
- Gretchen MichaelsonSouth Windsor$169K
- Kathryn JackMeriden$67K
- Lynn RapsilberTorrington$52K
- Genice NelsonFarmington$36K
- Andrea LauterNew London$32K
- Megan CarlucciManchester$28K
- Kellie HaleNew Haven$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.